International Conference on Targeting Diabetes and Novel Therapeutics September 14-16, 2015 Las Vegas, Nevada, USA

Dr. Ananya Manit has completed PhD at the age of 48 years (2 years ago) from College of Public Health Sciences, Chulalongkorn University, Thailand. I am a registered nurse and head of medicine ward since 1986 and 2006, King Narai Hospital, Lop Buri, Thailand. Furthermore, I worked as diabetes nurse case manager before I studied in doctoral degree. Currently, I worked as system manager of non-communicable disease in Mueang Lop Buri contracting unit of primary care therefore, I expert in field of diabetes and non-communicable disease.

Statistics data of Lop Buri Provincial Health Office indicated at least monks have as high risk of chronic disease (e.g. Diabetes, Hypertension, Dyslipidemia) as urban males of Mueang Lop Buri district, Lop Buri Province, Thailand. The purpose of this survey research was to study quality of life (QOL) of Buddhist Monks who were stayed in 10 temples of Mueang Lop Buri district, Lop Buri Province, Thailand. Data was collected by using WHOQOL - BREF – THAI questionnaire. Data analysis was calculated by descriptive analysis. The results showed that QOL of Buddhist monks were mean of 3.50 (middle level from 5 levels; lowest, low, middle, high, highest). The highest score disclosed that they thought their life had meaning with them, they satisfied in themselves, they needed to treatment for working, and their life to go on, and they went to some place by themselves. The lowest score showed they felt pain their body, and they felt bad such as sad, alone, upset in sometime. Therefore, health promotion services could be performed on health-care enhancing activities developed for quality of life of Buddhist monks.

Maria Laura Belladonna is Professor of Molecular Pharmacology at the University of Perugia and Researcher of the Department of Experimental Medicine (Pharmacology Section) of the University of Perugia since 1999. She received her degree in ‘Pharmaceutical Chemistry and Technology’ and PhD in ‘Experimental Medicine’ from the University of Perugia. She performed postdoctoral studies at the Ludwig Institute for Cancer Research in Brussels.\r\nDr. Belladonna’s research field is the study of dendritic cell functions, cytokines linked to immunological mechanisms driven by these cells, and the tolerogenic activity of tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO). She has published over 60 research articles and reviews (>7000 citations, H-index 37).\r\n

Dendritic cells (DCs) are specialized antigen presenting cells capable of triggering either stimulatory or regulatory T cell immune responses, according to their cell maturation state and microenvironment stimuli. IL-35, a heterodimeric cytokine belonging to the IL-12 family, is produced by regulatory T and B cells, and is known to induce a strong immunosuppressive response. In this study, we explored the possible regulatory and protective effect of IL-35 in a tolerogenic vaccination protocol aimed to prevent autoimmune diabetes in prediabetic NOD mice. \r\nTo this purpose we prepared murine splenic DCs transfected with an IL-35Ig single chain gene construct and loaded with IGRP peptide (one of the most relevant type 1 diabetes self-antigens) to be administered in a prophylactic cell therapy. Interestingly, we found that such IL-35Ig-producing and IGRP-presenting DCs—capable to suppress antigen specific, T cell-mediated responses in a skin test assay—induced in prediabetic NOD mice a delayed and less severe form of diabetes, an effect accompanied by the increase of CD4+CD39+ suppressive T cells in pancreatic lymph nodes. Protective immunosuppression achieved in this model suggests that DCs overexpressing ectopic IL-35Ig might represent a powerful tool in negative vaccination strategies. \r\n

Salma Mossad Eraky has completed her Master Degree at the age of 25 years from Mansoura University. She has published one paper in the Egyptian journal of Basic and Applied Sciences.

Fibroblast growth factor 21 (FGF21) is an effective regulator of glucose and lipid metabolism. It is mainly regulated by peroxisome proliferator activated receptors, and is widely associated with cases of insulin resistance as obesity and type 2 diabetes (T2D). Our study aimed to investigate the potential effects ofomega-3 fatty acids, pioglitazone, and their combination on serum and liver FGF21 concentrations, and its hepatic gene expression in a rat model of T2D. We also studied the modulating effects of these treatments on blood glucose, lipid profile, and insulin resistance. T2D was induced in male Sprague-Dawley rats by combination of high fat diet and low dose streptozotocin (35 mg/kg). Diabetic rats were treated with omega-3 fatty acids (10%W/W diet), pioglitazone (20 mg/kg), and their combination for a period of 4 weeks. Serum FGF21 concentration was significantly increased in diabetic rats. In contrast, hepatic FGF21 concentration, and gene expression were significantly decreased. Omega-3 fatty acids, pioglitazone, and their combination significantly decreased serum FGF21. Omega-3 fatty acids and combination therapy significantly decreased liver FGF21 concentration, with non-significant changes in gene expression. On the other hand, pioglitazone significantlyrnincreased hepatic FGF21 concentration and gene expression. Omega-3 fatty acids, pioglitazone and their combination significantly improved lipid profile. Pioglitazone and combination significantly decreased blood glucose levels and improved insulin resistance. In conclusion, this study introduces the first evidence regarding the anti-diabetic effects of omega-3 fatty acids and pioglitazone combination, such effects are mediated through FGF21.rn